Colchicine, a widely available gout medication, has been approved by the US Food and Drug Administration (FDA) for use in patients with coronary artery disease (CHD). In this respect informs Harry Perkins Institute for Medical Research.
The FDA’s decision was based on multiple studies involving thousands of patients with CAD. Clinical trials have proven the efficacy and safety of taking colchicine at a dose of 0.5 mg per day.
The drug was well tolerated by patients, did not cause an increased incidence of cancer, and did not interact with other common drugs, including statins. The latter is used to lower cholesterol levels and reduce the risk of heart attack and stroke by about 30%. Colchicine supplementation further reduces this risk.
With coronary heart disease, the lumen of the arteries of the heart narrows due to atherosclerotic plaques on the walls of blood vessels, which leads to impaired oxygen supply and increases the risk of heart attack and stroke. IHD is the leading cause of death worldwide and in many cases does not show any symptoms until a heart attack or stroke. The most likely explanation for the effect of colchicine may be attenuation of the inflammatory response in the vessels in coronary artery disease.
ancient scientists in your name Risk factors for colon or rectal cancer in men under 49 years of age.